0.83 USD
▼-0.17-16.82%
盘后 0.85 +2.49%
2026-09-15
市值
$145.28M
市盈率
—
EPS
-1.22
股息率
—
52 周区间
0.83 – 3.65
成交量
1.42M
Beta
2.74
目标价
6.14
52W 低 0.8352W 高 3.65
价格走势
公司简介
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and...